Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 103
Filter
2.
Biochim Biophys Acta ; 1818(4): 1039-48, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21835162

ABSTRACT

The design, synthesis, modeling and in vitro testing of channel-forming peptides derived from the cys-loop superfamily of ligand-gated ion channels are part of an ongoing research focus. Over 300 different sequences have been prepared based on the M2 transmembrane segment of the spinal cord glycine receptor α-subunit. A number of these sequences are water-soluble monomers that readily insert into biological membranes where they undergo supramolecular assembly, yielding channels with a range of selectivities and conductances. Selection of a sequence for further modifications to yield an optimal lead compound came down to a few key biophysical properties: low solution concentrations that yield channel activity, greater ensemble conductance, and enhanced ion selectivity. The sequence NK(4)-M2GlyR T19R, S22W (KKKKPARVGLGITTVLTMRTQW) addressed these criteria. The structure of this peptide has been analyzed by solution NMR as a monomer in detergent micelles, simulated as five-helix bundles in a membrane environment, modified by cysteine-scanning and studied for insertion efficiency in liposomes of selected lipid compositions. Taken together, these results define the structural and key biophysical properties of this sequence in a membrane. This model provides an initial scaffold from which rational substitutions can be proposed and tested to modulate anion selectivity. This article is part of a Special Issue entitled: Protein Folding in Membranes.


Subject(s)
Biophysical Phenomena , Peptides/chemistry , Protein Engineering , Receptors, Glycine/chemistry , Amino Acid Sequence , Animals , Anions , Circular Dichroism , Computer Simulation , Cysteine/genetics , Epithelial Cells/metabolism , Lipids/chemistry , Madin Darby Canine Kidney Cells , Magnetic Resonance Spectroscopy , Micelles , Models, Molecular , Molecular Sequence Data , Protein Structure, Secondary , Sodium Dodecyl Sulfate/chemistry , Solutions , Unilamellar Liposomes/chemistry
3.
Qual Saf Health Care ; 17(6): 409-15, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19064655

ABSTRACT

BACKGROUND: In 2005, guidance on how to prevent wrong site surgery in the form of a national safety alert was issued to all NHS hospital trusts in England and Wales by the National Patient Safety Agency. OBJECTIVE: To investigate the response to the alert among clinicians in England and Wales 12-15 months after it had been issued. METHODS: A before-after study, using telephone/face-to-face interviews with consultant surgeons and senior nurses in ophthalmology, orthopaedics and urology in 11 NHS hospitals in England & Wales in the year prior to the alert and 12-15 months after. The interviews were coded and analysed thematically. RESULTS: The study revealed marked heterogeneity in organisational processes in response to a national alert. There was a significant change in surgeons' self-reported practice, with only 48% of surgeons routinely marking patients prior to the alert and 85% after (p<0.001). However, inter-specialty differences remained and change in practice was not always matched by change in attitude. Compliance with the detailed recommendations about how marking should be carried out was inconsistent. There were unintended consequences in terms of greater bureaucracy and concerns about diffusion of responsibility and hastily performed marking to enable release of patients from wards. CONCLUSION: The alert was effective in promoting presurgical marking and encouraging awareness of safety issues in relation to correct site surgery. However, care should be taken to monitor unintended consequences and whether change is sustained. Greater flexibility for local adaptation coupled with better design and early testing of safety alerts prior to national dissemination may facilitate more sustainable changes in practice.


Subject(s)
Diffusion of Innovation , Medical Errors/prevention & control , Safety Management/methods , Attitude of Health Personnel , England , Humans , Interviews as Topic , Nursing Staff, Hospital , Physicians , State Medicine , Surveys and Questionnaires , Wales
4.
Leukemia ; 15(8): 1225-31, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11480564

ABSTRACT

Recombinant adenoviruses expressing wild-type p53 (AdWTp53) and p27KiP1 (Adp27) were used to compare the effects on cell cycle and apoptosis in SUDHL-1 cells derived from human anaplastic large cell lymphoma. Cells infected with AdWTp53 and Adp27 showed high level of wild-type p53 and p27KiP1 expression, respectively. The expression of these proteins resulted in G1 arrest after 24 h of infection. Although the cells persisted in G1 arrest in both cell populations after 48 and 72 h of infection, the level of apoptosis assessed by TUNEL analysis was higher in cells infected with AdWTp53. Interestingly, apoptosis was more pronounced in cells infected with Adp27 after the initial 24 h and reached a steady state at 48 and 72 h. A lower MOI of Adp27 resulted in G1 arrest associated with a low level of apoptosis in SUDHL-1 cells after 48 h of infection. This was correlated with lower expression of p27KiP1. We postulate that the time-lag and the different level of apoptosis occurring in SUDHL-1 cells infected with AdWTp53 and Adp27 are clearly related to the intrinsic biochemical pathways solicited. In this context our study provides a model to investigate these pathways and better understand the biology of this particular lymphoma. Our data also support a potential application of Adp27 for gene therapy of this lymphoma similarly to AdWTp53 as previously shown.


Subject(s)
Apoptosis/genetics , Cell Cycle Proteins/genetics , Cell Cycle/genetics , Genes, p53 , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/pathology , Tumor Suppressor Proteins , Adenoviridae , Cyclin-Dependent Kinase Inhibitor p27 , Gene Expression Regulation, Neoplastic , Genetic Vectors , Humans , Tumor Cells, Cultured
5.
J Gastroenterol Hepatol ; 16(5): 506-12, 2001 May.
Article in English | MEDLINE | ID: mdl-11350545

ABSTRACT

BACKGROUND: The trefoil peptide (TFF1) is a member of a family of mucin-associated regulatory peptides that are widely distributed in gastrointestinal tissues and have been implicated in the maintenance of the gastric mucosa. The role of TFF1 in gastric mucosal repair was examined by analysis of the spatio-temporal expression of TFF1 following gastric ulceration in the rat. METHODS: Gastric ulcers were induced in rats by application of glacial acetic acid to the serosa of the fundus. At various time points post injury (0-28 days), macroscopic and microscopic examination of the gastric mucosa was performed. In addition, the spatio-temporal expression of TFF1 protein and proliferating cell nuclear antigen were identified by immunohistochemistry, TFF1 message by in situ hybridization, and acidic/neutral secreting mucins by Alcian blue-periodic acid-Schiff staining. RESULTS: In normal rat gastric tissue, TFF1 peptide and mRNA were expressed in mucosal cells of the superficial epithelium. Trefoil peptide and mRNA were significantly induced between 4 and 28 days post ulceration, with expression extending beyond the superficial epithelium and being localized to acidic mucin-producing cells deep within the repairing mucosa. CONCLUSIONS: Spatio-temporal expression of TFF1 mRNA and peptide following macroscopic repair implicates TFF1 as a potential mediator of late stage-repair processes. Whether this is through direct stimulation of cellular differentiation or the enhancement of mucosal protective properties through an interaction with gastric mucins remains to be elucidated.


Subject(s)
Gastric Mucosa/metabolism , Proteins/metabolism , Stomach Ulcer/metabolism , Animals , Female , Immunohistochemistry , In Situ Hybridization , Male , Mucins/analysis , Proliferating Cell Nuclear Antigen/analysis , RNA, Messenger/analysis , Rats , Rats, Long-Evans , Time Factors , Trefoil Factor-1 , Tumor Suppressor Proteins
6.
J Mol Cell Cardiol ; 33(2): 317-29, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11162136

ABSTRACT

Carnitine palmitoyltransferase-I (CPT-I) is a major control point for fatty acid oxidation. Two kinetically different isoforms, CPT-I alpha and CPT-I beta, have been identified. Cardiac ventricular myocytes are the only cells known to express both CPT-I isoforms. In this study, we characterized the differential regulation of CPT-I alpha and CPT-I beta expression in the heart. Expression of the CPT-I alpha gene was very high in the fetal heart and declined following birth. CPT-I beta was also highly expressed in fetal myocytes and remained so throughout development. CPT-I alpha mRNA abundance was increased in both the liver and heart of diabetic or fasted rats, but CPT-I beta mRNA levels were not altered in these states. A high fat diet elevated expression of the CPT-I alpha gene in the liver but not in the heart. The fat content of the diet did not affect the expression of CPT-I beta. Cultures of neonatal rat cardiac myocytes were transfected with luciferase reporter genes driven by CPT-I alpha or CPT-I beta promoters. Two regions of the CPT-I alpha promoter, including an upstream region (-1300/-960) and a region in the proximal promoter (-193/-52) contributed equally to basal expression in cardiac myocytes. Basal transcription of CPT-I alpha was dependent on Sp1 sites and a CCAAT box in the proximal promoter. Our data indicate that the CPT-I beta gene is expressed in a tissue specific manner, but that it is not subject to the same developmental or hormonal controls imposed on CPT-I alpha. In addition some aspects of CPT-I alpha expression are confined to the liver. The data presented here thus suggest that two types of differential regulation of CPT-I genes exist: (a) differential control of CPT-I alpha and CPT-I beta gene expression in the heart and (b) differential regulation of CPT-I alpha expression in the heart and liver.


Subject(s)
Carnitine O-Palmitoyltransferase/genetics , Carnitine O-Palmitoyltransferase/metabolism , Gene Expression Regulation, Enzymologic , Myocardium/enzymology , Age Factors , Animals , Binding Sites , Carcinoma, Hepatocellular/metabolism , Carnitine O-Palmitoyltransferase/chemistry , Cell Nucleus/metabolism , Cells, Cultured , Diabetes Mellitus, Experimental/enzymology , Dietary Fats/pharmacology , Fatty Acids/metabolism , Female , Genes, Reporter , Genetic Vectors , Heart/embryology , Hyperthyroidism/enzymology , Kinetics , Liver/enzymology , Liver Neoplasms/metabolism , Luciferases/metabolism , Male , Myocardium/cytology , Promoter Regions, Genetic , Protein Isoforms , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Sp1 Transcription Factor/genetics , Time Factors , Tissue Distribution , Transfection , Tumor Cells, Cultured
7.
J Gastroenterol Hepatol ; 16(11): 1222-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11903739

ABSTRACT

BACKGROUND: Omeprazole is an inhibitor of the H+K+ ATPase of the gastric parietal cell, which is used clinically to suppress gastric acid secretion. It has also been found to inhibit gastric mucin production; however, its effects on the synthesis and secretion of the trefoil peptides, which are also expressed by mucus cells, and which play a key role in cytoprotection and epithelial repair, are unknown. METHODS: Rats (n=8) were given either omeprazole (30 mg/kg per day; p.o.) or inert carrier for 1 week, and the effects on synthesis and peptide expression of the gastric trefoil peptides, TFF1/pS2 and TFF2/SP, were compared. RESULTS: As expected, omeprazole treatment abolished H+ ion production with a mean gastric juice pH of 7.2 compared with 2.4 for controls. The omeprazole group had elevated total protein levels of 35-fold and TFF1/pS2 peptide levels elevated fourfold, respectively, but not TFF2/SP peptide in gastric juice, suggesting that the increased pH reduced the viscosity of adherent mucus, thereby increasing gastric juice concentrations by dissolution of adherent TFF1/pS2 and increased secretion. Concomitant with increased TFF1/pS2 secretion was a fall in predominantly antral mucosal trefoil peptide concentrations. In contrast to trefoil secretory rates, the steady-state synthesis of both TFF1/pS2 and TFF2/SP was unchanged after omeprazole treatment, implying both a large cellular pool of processed peptide and rapid secretion. CONCLUSION: The increase in the concentration of TFF1/pS2 in gastric secretions during chronic omeprazole-induced achlorhydria may be important in preventing tissue injury and promoting repair in response to an increased luminal bacterial population.


Subject(s)
Achlorhydria/metabolism , Gastric Mucosa/metabolism , Growth Substances/biosynthesis , Mucins , Muscle Proteins , Neuropeptides , Achlorhydria/chemically induced , Animals , Male , Omeprazole , Peptides , Rats , Rats, Wistar , Trefoil Factor-2 , Trefoil Factor-3
8.
J Biol Chem ; 275(45): 34989-97, 2000 Nov 10.
Article in English | MEDLINE | ID: mdl-10956641

ABSTRACT

Carnitine palmitoyltransferase I (CPT-I) catalyzes the transfer of long chain fatty acyl groups from CoA to carnitine for translocation across the mitochondrial inner membrane. CPT-Ialpha is a key regulatory enzyme in the oxidation of fatty acids in the liver. CPT-Ialpha is expressed in all tissues except skeletal muscle and adipose tissue, which express CPT-Ibeta. Expression of CPT-Ialpha mRNA and enzyme activity are elevated in the liver in hyperthyroidism, fasting, and diabetes. CPT-Ialpha mRNA abundance is increased 40-fold in the liver of hyperthyroid compared with hypothyroid rats. Here, we examine the mechanisms by which thyroid hormone (T3) stimulates CPT-Ialpha gene expression. Four potential T3 response elements (TRE), which contain direct repeats separated by four nucleotides, are located 3000-4000 base pairs 5' to the start site of transcription in the CPT-Ialpha gene. However, only one of these elements functions as a TRE. This TRE binds the T3 receptor as well as other nuclear proteins. Surprisingly, the first intron of the CPT-Ialpha gene is required for the T3 induction of CPT-Ialpha expression, but this region of the gene does not contain a TRE. In addition, we show that CPT-Ialpha is induced by T3 in cell lines of hepatic origin but not in nonhepatic cell lines.


Subject(s)
Carnitine O-Palmitoyltransferase/genetics , Carnitine O-Palmitoyltransferase/metabolism , Gene Expression Regulation, Enzymologic , Introns , Promoter Regions, Genetic , Thyroid Hormones/metabolism , Amino Acid Sequence , Animals , Animals, Newborn , Cell Line , Cell Nucleus/metabolism , Cells, Cultured , Deoxyribonuclease I/metabolism , Escherichia coli/metabolism , Fatty Acids/metabolism , Humans , Liver/enzymology , Luciferases/metabolism , Models, Genetic , Molecular Sequence Data , Mutagenesis, Site-Directed , Myocardium/metabolism , Polymerase Chain Reaction , RNA, Messenger/metabolism , Rats , Recombinant Proteins/metabolism , Response Elements , Sequence Analysis, DNA , Transfection , Triiodothyronine/metabolism
9.
Am J Physiol Gastrointest Liver Physiol ; 278(6): G839-46, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10859212

ABSTRACT

Adaptation of the gastric mucosa to nonsteroidal anti-inflammatory drug-induced injury is a well-documented phenomenon, but the mechanisms are not known. We investigated whether changes in stress protein expression and apoptosis play roles in adaptation of rat stomach to aspirin. RT-PCR and Western blotting techniques were used to analyze mRNA and protein expression of HSP72 and HSP90 and cleavage of caspase 3 protein. Apoptosis was detected by the TUNEL method and quantified. HSP72 mRNA and protein expression was unchanged in adapted mucosa, whereas HSP90 mRNA and protein levels decreased. Caspase 3 protein was activated, and the number of apoptotic cells increased in mucosa after one aspirin dose. However, in adapted mucosa after aspirin, activated caspase 3 and the number of apoptotic cells had returned to basal levels. Induction of the stress response was found not to be a mechanism of mucosal adaptation against multiple doses of aspirin. Our results lead us to propose instead that resistance to aspirin-induced apoptosis plays a role in the protective phenomenon of adaptation.


Subject(s)
Adaptation, Physiological/physiology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/physiology , Aspirin/pharmacology , Stomach/drug effects , Stomach/physiopathology , Animals , Caspase 3 , Caspases/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Gastric Mucosa/physiopathology , HSP72 Heat-Shock Proteins , Heat-Shock Proteins/genetics , Heat-Shock Proteins/metabolism , Hot Temperature , Male , RNA, Messenger/metabolism , Rats , Rats, Long-Evans , Reference Values , Reverse Transcriptase Polymerase Chain Reaction
11.
Proc Natl Acad Sci U S A ; 96(22): 12935-40, 1999 Oct 26.
Article in English | MEDLINE | ID: mdl-10536026

ABSTRACT

Vegetable oils that contain fatty acids with conjugated double bonds, such as tung oil, are valuable drying agents in paints, varnishes, and inks. Although several reaction mechanisms have been proposed, little is known of the biosynthetic origin of conjugated double bonds in plant fatty acids. An expressed sequence tag (EST) approach was undertaken to characterize the enzymatic basis for the formation of the conjugated double bonds of alpha-eleostearic (18:3Delta(9cis, 11trans,13trans)) and alpha-parinaric (18:4Delta(9cis,11trans, 13trans,15cis)) acids. Approximately 3,000 ESTs were generated from cDNA libraries prepared from developing seeds of Momordica charantia and Impatiens balsamina, tissues that accumulate large amounts of alpha-eleostearic and alpha-parinaric acids, respectively. From ESTs of both species, a class of cDNAs encoding a diverged form of the Delta(12)-oleic acid desaturase was identified. Expression of full-length cDNAs for the Momordica (MomoFadX) and Impatiens (ImpFadX) enzymes in somatic soybean embryos resulted in the accumulation of alpha-eleostearic and alpha-parinaric acids, neither of which is present in untransformed soybean embryos. alpha-Eleostearic and alpha-parinaric acids together accounted for as much as 17% (wt/wt) of the total fatty acids of embryos expressing MomoFadX. These results demonstrate the ability to produce fatty acid components of high-value drying oils in transgenic plants. These findings also demonstrate a previously uncharacterized activity for Delta(12)-oleic acid desaturase-type enzymes that we have termed "conjugase."


Subject(s)
Fatty Acids/biosynthesis , Glycine max/metabolism , Plants, Genetically Modified/metabolism , Amino Acid Sequence , Base Sequence , DNA Primers , DNA, Complementary , Expressed Sequence Tags , Fatty Acid Desaturases/genetics , Molecular Sequence Data , Plants, Genetically Modified/embryology , Plants, Genetically Modified/enzymology , Recombinant Proteins/genetics , Saccharomyces cerevisiae/genetics , Seeds/enzymology , Sequence Homology, Amino Acid , Glycine max/embryology , Glycine max/enzymology
12.
Exp Cell Res ; 251(2): 356-71, 1999 Sep 15.
Article in English | MEDLINE | ID: mdl-10471321

ABSTRACT

The role of CD9 in cell adhesion and spreading on adhesive proteins was investigated using a transfected Chinese hamster ovary (CHO) cell system. CD9 cell surface expression resulted in reduced adhesion and increased spreading on fibronectin (Fn). Whereas mock-transfected (mock CHO) and naïve CHO cells assumed a typical fibroblast spindle shape morphology, CD9-transfected (CD9-CHO) cells were polygonal with many filipodial projections and exhibited a twofold greater surface area. The spread morphology of CD9-CHO cells, but not mock CHO cells, was inhibited by PB1 mAb blockade of alpha(5)beta(1), suggesting that the coexpression of alpha(5)beta(1) and CD9 influenced cell activity on Fn. The second extracellular loop of CD9 was implicated in regulation of adhesion since reduced CD9-CHO cell adhesion on Fn was reversed by either anti-CD9 antibody ligation to the second extracellular loop or with cells expressing a CD9 mutant lacking the second extracellular loop domain. Using cell adhesion assays and ELISA, we demonstrated CD9 binding to the HEP2/IIICS region of Fn. Finally, CD9 expression resulted in a twofold reduction in Fn-rich pericellular matrix assembly. Our observations show that CD9 dramatically influences CHO cell interactions with Fn and suggest that CD9 has an important role in modulating cell-extracellular matrix interactions.


Subject(s)
Antigens, CD/metabolism , Cell Adhesion/physiology , Cell Membrane/metabolism , Extracellular Matrix/metabolism , Fibronectins/metabolism , Membrane Glycoproteins/metabolism , Animals , Antigens, CD/genetics , CHO Cells , Cell Size , Cricetinae , Humans , Integrins/metabolism , Peptide Fragments/metabolism , Protein Binding , Receptors, Fibronectin/metabolism , Recombinant Proteins/metabolism , Sequence Deletion , Structure-Activity Relationship , Tetraspanin 29
13.
FEBS Lett ; 456(1): 155-9, 1999 Jul 30.
Article in English | MEDLINE | ID: mdl-10452549

ABSTRACT

Members of the trefoil factor (TFF) family are mucin-associated polypeptides that are expressed along the entire length of the gastrointestinal tract. TFFs have been proposed to play a role in mucosal defence through both protective and reparative mechanisms. The potential relationship between TFFs and mucins in non-gut glycoprotein-secreting epithelia has not been fully explored. In the present study we identified TFF2 and TFF3 mRNA and peptide in rat lymphoid tissues, demonstrated that TFF peptide expression in rat spleen increased 1.5- to 3-fold following experimental induction of the immune response, and showed that hTFF2 and hTFF3 (1-5 mg/ml) stimulated migration of human monocytes. Our data suggest that TFFs may in part be involved in the repair of injury through the modulation of the inflammatory response.


Subject(s)
Growth Substances/metabolism , Growth Substances/pharmacology , Immune System/metabolism , Lymphoid Tissue/metabolism , Mucins , Muscle Proteins , Neuropeptides , Peptides/metabolism , Peptides/pharmacology , Proteins/metabolism , Proteins/pharmacology , Animals , Cell Movement/drug effects , Female , Humans , Lipopolysaccharides/pharmacology , Male , Monocytes/drug effects , Monocytes/immunology , Proteins/genetics , RNA, Messenger , Rats , Rats, Long-Evans , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Spleen/drug effects , Spleen/immunology , Spleen/metabolism , Trefoil Factor-2 , Trefoil Factor-3
14.
Am J Med Sci ; 318(1): 43-8, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10408760

ABSTRACT

Two genes control expression of mitochondrial carnitine palmitoyltransferase-I (CPT-I), the enzyme that catalyzes the primary rate-controlling step in fatty acid oxidation. Two CPT-I isoforms have been found--a "liver" isoform (CPT-Ialpha) expressed in most tissues, but not in skeletal muscles, and a "muscle" isoform (CPT-Ibeta) expressed in muscles and adipocytes. Liver CPT-Ialpha increases dramatically at birth, but heart CPT-Ialpha is abundant in the fetus and diminishes at birth. Insulin, thyroid hormone, and fatty acids regulate expression of CPT-Ialpha in liver, whereas electrical stimulation increases CPT-Ibeta and decreases CPT-Ialpha in cardiac myocytes. Both genes are TATA-less and contain Sp1 transcription factor binding sites upstream of the start site of transcription. Multiple transcripts of both CPT-Ialpha and CPT-Ibeta exist, some of which may have roles in regulating fatty acid oxidation.


Subject(s)
Carnitine O-Palmitoyltransferase/genetics , Fatty Acids/metabolism , Gene Expression Regulation, Enzymologic , Mitochondria/enzymology , Animals , Humans , Isoenzymes/genetics , Mitochondria, Heart/enzymology , Mitochondria, Liver/enzymology , Oxidation-Reduction
15.
Biochem J ; 340 ( Pt 2): 425-32, 1999 Jun 01.
Article in English | MEDLINE | ID: mdl-10333485

ABSTRACT

Carnitine palmitoyltransferase (CPT)-I catalyses the transfer of long-chain fatty acids from CoA to carnitine for translocation across the mitochondrial inner membrane. Expression of the 'liver' isoform of the CPT-I gene (CPT-Ialpha) is subject to developmental, hormonal and tissue-specific regulation. To understand the basis for control of CPT-Ialpha gene expression, we have characterized the proximal promoter of the CPT-Ialpha gene. Here, we report the sequence of 6839 base pairs of the promoter and the localization of the rat CPT-Ialpha gene to region q43 on chromosome 1. Our studies show that the first 200 base pairs of the promoter are sufficient to drive transcription of the CPT-Ialpha gene. Within this region are two sites that bind both Sp1 and Sp3 transcription factors. In addition, nuclear factor Y (NF-Y) binds the proximal promoter. Mutation at the Sp1 or NF-Y sites severely decreases transcription from the CPT-Ialpha promoter. Other protein binding sites were identified within the first 200 base pairs of the promoter by DNase I footprinting, and these elements contribute to CPT-Ialpha gene expression. Our studies demonstrate that CPT-Ialpha is a TATA-less gene which utilizes NF-Y and Sp proteins to drive basal expression.


Subject(s)
Carnitine O-Palmitoyltransferase/genetics , Chromosome Mapping , DNA-Binding Proteins/physiology , Gene Expression Regulation, Enzymologic/physiology , Liver/enzymology , Promoter Regions, Genetic , Sp1 Transcription Factor/physiology , Animals , Base Sequence , CCAAT-Enhancer-Binding Proteins , DNA , In Situ Hybridization, Fluorescence , Molecular Sequence Data , Rats , Tumor Cells, Cultured
16.
Gut ; 44(5): 636-42, 1999 May.
Article in English | MEDLINE | ID: mdl-10205199

ABSTRACT

BACKGROUND: The trefoil peptides are major secretory products of mucus cells of the gastrointestinal tract and show increased expression after inflammatory or ulcerative damage. Recombinant human TFF2 (spasmolytic polypeptide) has been shown to be cytoprotective, and enhances repair in models of gastric injury. AIMS: To test the healing effects of recombinant human (h)TFF2 in a rat model of chronic colitis. METHODS: Colitis was induced by intracolonic administration of dinitrobenzene sulphonic acid in ethanol. Mucosal repair was quantified macroscopically, microscopically by image analysis of tissue histology, and by measuring myeloperoxidase activity. RESULTS: Initial validation studies showed that maximal injury and inflammation occurred at the end of the first week after colitis induction (active phase), and that spontaneous healing was complete by eight weeks. Once daily intrarectal application of hTFF2 (2.5 mg/kg; approximately 0.5 mg/rat) for five days after maximal damage had been sustained, reduced both microscopic and macroscopic injury by 80% and inflammatory index by 50% compared with vehicle controls. In addition, endogenous concentrations of rat TFF2 and TFF3 (intestinal trefoil factor) were increased in the active phase of colitis and were reduced to basal levels by hTFF2 treatment. CONCLUSIONS: This study has shown that hTFF2 enhances the rate of colonic epithelial repair, and reduces local inflammation in a rat model of colitis, and suggests that luminal application of trefoil peptides may have therapeutic potential in the treatment of inflammatory bowel disease.


Subject(s)
Colitis/drug therapy , Growth Substances/therapeutic use , Mucins , Muscle Proteins , Neuropeptides , Peptides/therapeutic use , Administration, Rectal , Animals , Benzenesulfonates , Chronic Disease , Colitis/chemically induced , Colitis/pathology , Disease Models, Animal , Ethanol , Humans , Male , Peroxidase/metabolism , Rats , Rats, Wistar , Recombinant Proteins/therapeutic use , Trefoil Factor-2 , Trefoil Factor-3
17.
Adv Exp Med Biol ; 466: 27-42, 1999.
Article in English | MEDLINE | ID: mdl-10709625

ABSTRACT

Our earlier work using intact mitochondria and isolated mitochondrial outer membranes confirms the observations of Murthy and Pande that CPT-I is located on the mitochondrial outer membranes and supports the notion that this enzyme has a malonyl-CoA binding domain facing the cytosol and an acyl-CoA binding domain facing the inter membrane space. Our data also suggests that coenzyme A binds at the active site of CPT-I, as does acyl-CoA, 2-bromopalmitoyl-CoA, and (+)-hemipalmitoylcarnitinium, but malonyl-CoA does not bind at that site. Inhibition of CPT-I at the malonyl-CoA binding site by HPG and Ro 25-0187, which have no CoA moiety, contributes to a resolution of this question in that the CoA itself is not essential for the binding of malonyl-CoA to its regulatory site, but the dicarbonyl function which is present in malonyl-CoA, HPG, and Ro 25-0187 is absolutely essential. Our re-evaluation of the topology of hepatic mitochondrial CPT-I confirms the original observations that this enzyme has at least two different binding domains, one domain binding malonyl-CoA, HPG, and Ro-25-187 and the other domain binding acyl-CoA and other inhibitors of CPT-I. Furthermore, the malonyl-CoA binding domain is exposed to the cytosolic face of the membrane. Our data showing that treatment of the intact mitochondria with trypsin causes release of adenylate kinase which indicates that trypsin has damaged the mitochondrial outer membrane, possibly allowing trypsin to enter the intermembrane space and act on CPT from within the outer membrane. Since trypsin's action is limited to arginine and lysine residues, an alternative explanation could be that the portion of the protein domain responsible for malonyl-CoA inhibition may not contain these residues. The latter explanation is plausible, since malonyl-CoA was able to protect against loss of activity and sensitivity to inhibition, but did not protect against loss of adenylate kinase, suggesting that rupture of the outer membrane is not necessarily related to loss of CPT activity. These results suggest that some protein domain that is necessary for CPT activity is exposed on the outer surface of the outer membranes. Therefore, it seems likely that trypsin would have to be able to hydrolyse protein domains of CPT that are inaccessible to Nagarse and papain.


Subject(s)
Carnitine O-Palmitoyltransferase/chemistry , Carnitine O-Palmitoyltransferase/metabolism , Mitochondria, Liver/enzymology , Animals , Binding Sites , Carnitine O-Palmitoyltransferase/antagonists & inhibitors , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Humans
18.
Int J Dev Biol ; 42(6): 783-9, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9727834

ABSTRACT

Trefoil peptides are members of a unique family of proteins found predominately throughout the gastrointestinal tract, whose proposed functions include mucus stabilization, stimulation and/or differentiation of epithelial cells during wound repair. Recent trefoil knockout studies have reported delays in epithelial cell migration or maturation pathways together with almost a complete lack of mucus. In order to fully explore the role of trefoil peptides in gastrointestinal maturation, these studies were undertaken to accurately characterize the expression of trefoil peptides in the developing rat gut. The results of RPA suggest that trefoil mRNA's are expressed as early as 15 days post coitus (dpc) in the intestine and stomach. Proteins are detected at 17 dpc by radioimmunoassay and immunohistochemical studies, which localize trefoil peptide expression to the lumenal surface of epithelial cells. At 17 dpc the gut is lined by pseudo-stratified, undifferentiated epithelial cells. Polarized, columnar cells are not detected until at least 18 dpc, with sparse mucus staining and parietal cell markers not being detected until 18 and 19 dpc respectively. This data demonstrates that trefoil peptides are early markers of epithelial cell maturation in the developing rat gut. The time course of their expression, well before the mucus cell type is specified, suggests a potential role in epithelial cell differentiation.


Subject(s)
Gene Expression Regulation, Developmental/physiology , Growth Substances/genetics , Intestines/embryology , Mucins , Muscle Proteins , Neuropeptides , Peptides/genetics , Stomach/embryology , Animals , Biomarkers , Epithelium/chemistry , Growth Substances/analysis , Intestinal Mucosa , Intestines/chemistry , Peptides/analysis , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Stomach/chemistry , Trefoil Factor-2 , Trefoil Factor-3
20.
J Gastroenterol Hepatol ; 13(4): 363-70, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9641298

ABSTRACT

Spasmolytic polypeptide (SP) is a member of the trefoil peptide family; gut peptides that participate in the protection and repair of the gastric mucosa. Previous studies have failed to agree on the mode of action of human SP (hSP). We investigated the effect of orally administered human SP on the protection and repair of rat gastric mucosa in an established in vivo model of damage induced by the non-steroidal anti-inflammatory drug aspirin (ASA). The integrity of the gastric mucosa was quantified in four ways: the temporal change in transmucosal potential difference (PD), area of macroscopic damage by planimetry, relative area of microscopic damage by histological morphometry, and the number of deep erosions per centimetre of mucosa sectioned. Human SP (200 micromol/L) administered orally before, or in combination with ASA significantly reduced the fall in PD, the area of microscopic damage, and the number of deep erosions (P < 0.05). The area of macroscopic damage was significantly reduced only in rats where hSP (200 micromol/L) was given in conjunction with ASA (P < 0.05). Human spasmolytic polypeptide (70 or 200 micromol/L) administered after ASA failed to hasten the re-establishment of PD or stimulate the repair of the gastric mucosa in the 90 min following injury (P > 0.05, compared with ASA alone). We conclude that hSP prevents gastric mucosal damage by its topical actions, probably by a rapid interaction with luminal mucins or epithelial cells, but fails to stimulate early restitution in the injured gastric mucosa.


Subject(s)
Aspirin/adverse effects , Gastric Mucosa/drug effects , Mucins , Muscle Proteins , Neuropeptides , Parasympatholytics/pharmacology , Peptides/pharmacology , Administration, Oral , Animals , Dose-Response Relationship, Drug , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Gastric Mucosa/physiology , Humans , Intercellular Signaling Peptides and Proteins , Male , Membrane Potentials/drug effects , Parasympatholytics/administration & dosage , Parasympatholytics/metabolism , Rats , Time Factors , Trefoil Factor-2 , Trefoil Factor-3
SELECTION OF CITATIONS
SEARCH DETAIL
...